Cover Image
市場調查報告書

血漿分餾製劑的全球市場的預測 ∼2021年:白蛋白、免疫球蛋白、第八凝血因子、蛋白分解酵素抑制劑

Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Immunology), End User (Hospitals, Clinical Research Laboratories) - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 365863
出版日期 內容資訊 英文 222 Pages
訂單完成後即時交付
價格
Back to Top
血漿分餾製劑的全球市場的預測 ∼2021年:白蛋白、免疫球蛋白、第八凝血因子、蛋白分解酵素抑制劑 Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Immunology), End User (Hospitals, Clinical Research Laboratories) - Global Forecast to 2021
出版日期: 2016年08月04日 內容資訊: 英文 222 Pages
簡介

全球血漿分餾製劑的市場在預測期間內,預計以6.7%的年複合成長率發展,從2016年的188億4000萬美元,成長到2021年的260億7000萬美元的規模。人口的高齡化,出血性疾病和免疫疾病的增加,免疫球蛋白和阿爾法1-抗胰蛋白酶的利用擴大等促進該市場的成長。

本報告提供全球血漿分餾製劑的市場調查,市場及產品概要,產業趨勢,影響市場成長因素及市場機會分析,各產品、用途、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場概要
  • 亞太地區市場
  • 各地區的成長機會
  • 地區結構
  • 先進國家市場 vs 新興國家市場

第5章 血漿分餾製劑的全球市場:概要

  • 簡介
  • 市場動態
  • 主要的成長推進因素
  • 主要的阻礙成長要素
  • 主要市場機會
  • 主要課題

第6章 血漿分餾製劑的全球市場:產業分析

  • 簡介
  • 產業趨勢
  • 波特的五力分析

第7章 全球血漿分餾製劑市場:各產品

  • 簡介
  • 刻度流程
  • 免疫球蛋白
    • IVIG (免疫球蛋白大量靜附註)
    • SCIG (皮下注射用免疫球蛋白製劑)
    • 其他
  • 凝血因子濃縮製劑
    • 第八凝血因子
    • 第九凝血因子
    • VWF (血友病因子)
    • PCC (凝血素原複合體製劑)
    • 纖維蛋白原濃縮物
    • 凝血因子XIII
  • 白蛋白
  • 蛋白分解酵素抑制劑
  • 其他

第8章 全球血漿分餾製劑市場:各用途

  • 簡介
  • 神經
  • 免疫
  • 血液
  • 重症加護
  • 呼吸系統
  • 血液腫瘤
  • 風濕
  • 其他

第9章 全球血漿分餾製劑市場:各終端用戶

  • 簡介
  • 醫院、診療所
  • 臨床研究實驗室
  • 學術機構

第10章 全球血漿分餾製劑市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他
  • 其他地區
    • 南美
    • 中東、非洲

第11章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢
    • 擴張
    • 協定、合作、聯盟
    • 新產品的投入
    • 收購

第12章 企業簡介

  • 介紹
  • CSL LTD.
  • GRIFOLS S.A.
  • BAXALTA INCORPORATED
  • OCTAPHARMA AG
  • KEDRION S.P.A
  • LFB S.A.
  • BIOTEST AG
  • SANQUIN
  • CHINA BIOLOGIC PRODUCTS, INC.
  • BIO PRODUCT LABORATORY LTD. (BPL)

第13章 附錄

目錄
Product Code: PH 4477

The global plasma fractionation market is estimated to grow at a CAGR of 6.7% from 2016 to 2021, to reach USD 26.07 billion by 2021 from USD 18.84 billion in 2016. Growth in this market is mainly attributed to growing aging population, rising incidences of bleeding and immune disorders, and growing use of immunoglobulin and alpha-1-antitrypsin. However, the high cost of plasma products, adverse reactions associated with use of products, and limited reimbursement policies can hinder the growth of this market. Moreover, the increasing usage of recombinant coagulation factors as an alternative to plasma-derived coagulation factors is further hampering the growth of this market to a certain extent.

In this report, the plasma fractionation market is segmented on the basis of products, applications, end users, and regions. In 2015, the immunoglobulin segment accounted for the largest share of the global plasma fractionation market, by product. The large share of this segment can primarily be attributed to the rising incidences of neurological and immunological diseases, growing use of intravenous immunoglobulin (IVIg) in various therapeutic areas, and rising adoption of subcutaneous immunoglobulin (SCIg). On the basis of application, neurology segment accounted for the largest share of the plasma fractionation market. In 2015, hospitals and clinics accounted for the largest share of global plasma fractionation market, by end-user. This large share for hospitals and clinics is due to increasing use of plasma products for labeled and off-labeled use for the treatment of various diseases in hospitals and clinics. In addition, the improvement of healthcare infrastructure in hospitals and clinics in emerging countries is expected to support the growth of this segment.

Geographically, North America commanded a major share of the plasma fractionation market in 2015. However, Asia-Pacific is expected to witness the highest growth rate during the forecast period. Growth in the Asia-Pacific market can be attributed to the rapid growth in the aging population, increasing use of albumin and immunoglobulin, and increasing number of hemophilic patients.

Some of the prominent players in the plasma fractionation market include CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (Germany), LFB S.A (France), Bio Product Laboratory Ltd. (U.K.), and Sanquin (Netherlands).

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering greater market shares. Firms purchasing the report could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for increasing their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the service portfolios offered by the top players in the plasma fractionation market. The report analyzes the plasma fractionation market by product, application, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming trends, research and development activities, and new services launches in the plasma fractionation market
  • Market Development: Comprehensive information about the lucrative emerging markets by product and region
  • Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the plasma fractionation market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and services, and testing capabilities of leading players in the plasma fractionation market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
    • 2.1.1. SECONDARY SOURCES
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY SOURCES
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. PLASMA FRACTIONATION MARKET OVERVIEW
  • 4.2. ASIA-PACIFIC PLASMA FRACTIONATION MARKET
  • 4.3. PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4. PLASMA FRACTIONATION MARKET: GEOGRAPHIC MIX
  • 4.5. PLASMA FRACTIONATION MARKET: DEVELOPING VS. DEVELOPED COUNTRIES

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
  • 5.3. KEY MARKET DRIVERS
    • 5.3.1. GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS
    • 5.3.2. RISE IN THE AGING POPULATION ACROSS THE GLOBE
    • 5.3.3. GROWING PREVALENCE OF RESPIRATORY DISEASES AND AATD DRIVING THE UPTAKE OF ALPHA-1 ANTITRYPSIN
    • 5.3.4. INCREASE IN PLASMA COLLECTION
  • 5.4. KEY MARKET RESTRAINTS
    • 5.4.1. HIGH COST AND LIMITED REIMBURSEMENTS
    • 5.4.2. STRINGENT GOVERNMENT REGULATIONS
    • 5.4.3. EMERGENCE OF RECOMBINANT ALTERNATIVES
  • 5.5. KEY MARKET OPPORTUNITIES
    • 5.5.1. INCREASING NUMBER OF HEMOPHILIC PATIENTS
  • 5.6. KEY CHALLENGES
    • 5.6.1. PRICING PRESSURE FACED BY PROMINENT PLAYERS IN THE MARKET

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. KEY INDUSTRY TRENDS
    • 6.2.1. FOCUS ON INCREASING FRACTIONATION CAPACITIES AND GEOGRAPHICAL EXPANSIONS
    • 6.2.2. NEW INDICATIONS FOR PLASMA PRODUCTS
    • 6.2.3. RISING ADOPTION OF SCIG
    • 6.2.4. INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS
    • 6.2.5. GROWING PLASMA PRODUCTS MARKET IN CHINA
    • 6.2.6. INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPMENT OF RECOMBINANT FACTORS
  • 6.3. PORTER'S FIVE FORCES ANALYSIS
    • 6.3.1. THREAT OF NEW ENTRANTS
    • 6.3.2. THREAT OF SUBSTITUTES
    • 6.3.3. BARGAINING POWER OF SUPPLIERS
    • 6.3.4. BARGAINING POWER OF BUYERS
    • 6.3.5. INTENSITY OF COMPETITIVE RIVALRY

7. GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. FRACTIONATION PROCESS
  • 7.3. IMMUNOGLOBULIN
    • 7.3.1. INTRAVENOUS IMMUNOGLOBULIN
    • 7.3.2. SUBCUTANEOUS IMMUNOGLOBULIN
    • 7.3.3. OTHER IMMUNOGLOBULINS
  • 7.4. COAGULATION FACTOR CONCENTRATES
    • 7.4.1. FACTOR VIII
    • 7.4.2. FACTOR IX
    • 7.4.3. VON WILLEBRAND FACTOR (VWF)
    • 7.4.4. PROTHROMBIN COMPLEX CONCENTRATES
    • 7.4.5. FIBRINOGEN CONCENTRATES
    • 7.4.6. FACTOR XIII
  • 7.5. ALBUMIN
  • 7.6. PROTEASE INHIBITORS
  • 7.7. OTHER PLASMA PRODUCTS

8. GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. NEUROLOGY
  • 8.3. IMMUNOLOGY
  • 8.4. HEMATOLOGY
  • 8.5. CRITICAL CARE
  • 8.6. PULMONOLOGY
  • 8.7. HEMATO-ONCOLOGY
  • 8.8. RHEUMATOLOGY
  • 8.9. OTHER APPLICATIONS

9. GLOBAL PLASMA FRACTIONATION MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS AND CLINICS
  • 9.3. CLINICAL RESEARCH LABORATORIES
  • 9.4. ACADEMIC INSTITUTES

10. GLOBAL PLASMA FRACTIONATION MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. ITALY
    • 10.3.4. SPAIN
    • 10.3.5. U.K.
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA-PACIFIC (RO-APAC)
  • 10.5. REST OF THE WORLD (ROW)
    • 10.5.1. LATIN AMERICA
    • 10.5.2. MIDDLE EAST AND AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. EXPANSIONS
    • 11.3.2. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 11.3.3. NEW PRODUCT LAUNCHES
    • 11.3.4. ACQUISITIONS

12. COMPANY PROFILES (Business Overview, Company Snapshot, Recent Developments, & MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. CSL LTD.
  • 12.3. GRIFOLS S.A.
  • 12.4. BAXALTA INCORPORATED
  • 12.5. OCTAPHARMA AG
  • 12.6. KEDRION S.P.A
  • 12.7. LFB S.A.
  • 12.8. BIOTEST AG
  • 12.9. SANQUIN
  • 12.10. CHINA BIOLOGIC PRODUCTS, INC.
  • 12.11. BIO PRODUCT LABORATORY LTD. (BPL)

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. OTHER DEVELOPMENTS
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.7. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
  • TABLE 2: GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS ARE DRIVING MARKET GROWTH
  • TABLE 3: HIGH COST AND LIMITED REIMBURSEMENTS ARE RESTRAINING MARKET GROWTH
  • TABLE 4: INCREASING NUMBER OF HEMOPHILIC PATIENTS PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES
  • TABLE 5: PRICING PRESSURE FACED BY PROMINENT PLAYERS IN THE MARKET IS A MAJOR MARKET CHALLENGE
  • TABLE 6: FRACTIONATION CAPACITY EXPANSION BY MAJOR PLAYERS
  • TABLE 7: PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2012)
  • TABLE 8: MAJOR LOCAL PLAYERS IN CHINA
  • TABLE 9: REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS
  • TABLE 10: GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 11: GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 12: GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 13: GLOBAL IMMUNOGLOBULIN MARKET SIZE, 2014-2021 (METRIC TONS)
  • TABLE 14: GLOBAL IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 15: GLOBAL IVIG MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 16: GLOBAL SCIG MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 17: GLOBAL OTHER IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 18: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 19: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY/REGION, 2014-2021(USD MILLION)
  • TABLE 20: GLOBAL FACTOR VIII MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 21: GLOBAL FACTOR VIII MARKET SIZE, 2014-2021 ( MILLION INTERNATIONAL UNITS)
  • TABLE 22: GLOBAL FACTOR IX MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 23: GLOBAL VWF MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 24: GLOBAL PCC MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 25: FIBRINOGEN CONCENTRATES MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 26: GLOBAL FACTOR XIII MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 27: GLOBAL ALBUMIN MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 28: GLOBAL ALBUMIN MARKET SIZE, 2014-2021 (METRIC TONS)
  • TABLE 29: GLOBAL PROTEASE INHIBITORS MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 30: GLOBAL OTHER PLASMA PRODUCTS MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 31: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 32: NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AS PERCENTAGE OF GLOBAL DALYS (2005, 2015, & 2030)
  • TABLE 33: PLASMA FRACTIONATION MARKET SIZE FOR NEUROLOGY APPLICATIONS, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 34: PLASMA FRACTIONATION MARKET SIZE FOR IMMUNOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 35: GLOBAL NUMBER OF HEMOPHILIC PATIENTS (2012-2014)
  • TABLE 36: PLASMA FRACTIONATION MARKET SIZE FOR HEMATOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 37: PLASMA FRACTIONATION MARKET SIZE FOR CRITICAL CARE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 38: PLASMA FRACTIONATION MARKET SIZE FOR PULMONOLOGY APPLICATIONS, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 39: ESTIMATED INCIDENCE AND MORTALITY RATE OF BLOOD CANCER TYPES IN DEVELOPED AND DEVELOPING COUNTRIES, BY SEX, 2012
  • TABLE 40: PLASMA FRACTIONATION MARKET SIZE FOR HEMATO-ONCOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 41: PLASMA FRACTIONATION MARKET SIZE FOR RHEUMATOLOGY, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 42: PLASMA FRACTIONATION MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 43: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 44: GLOBAL PLASMA FRACTIONATION MARKET SIZE FOR HOSPITALS AND CLINICS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 45: CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN
  • TABLE 46: GLOBAL PLASMA FRACTIONATION MARKET SIZE FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 47: GLOBAL PLASMA FRACTIONATION MARKET SIZE FOR ACADEMIC INSTITUTES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 48: GLOBAL PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 49: NORTH AMERICA: TOTAL HEMOPHILIA PATIENTS, 2013 VS. 2014
  • TABLE 50: NORTH AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 51: NORTH AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 52: NORTH AMERICA: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 53: NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 54: NORTH AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 55: NORTH AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 56: DISTRIBUTION OF PRIMARY IMMUNODEFICIENCY PATIENTS IN THE U.S., 2014
  • TABLE 57: PEOPLE WITH HEMOPHILIA A & HEMOPHILILA B IN U.S., 2013-2014
  • TABLE 58: U.S.: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 59: U.S.: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 60: U.S.: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 61: U.S.: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 62: U.S.: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 63: CANADA: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 64: CANADA: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 65: CANADA: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 66: CANADA: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 67: CANADA: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 68: EUROPE: PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 69: EUROPE: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 70: EUROPE: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 71: EUROPE: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 72: EUROPE: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 73: EUROPE: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 74: GERMANY: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 75: GERMANY: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 76: GERMANY: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 77: GERMANY: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 78: GERMANY: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 79: NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE : 2012-2014
  • TABLE 80: FRANCE: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 81: FRANCE: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 82: FRANCE: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 83: FRANCE: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 84: FRANCE: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 85: PRODUCTION OF PLASMA PRODUCTS IN ITALY: 2013
  • TABLE 86: ITALY: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 87: ITALY: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 88: ITALY: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 89: ITALY: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 90: ITALY: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 91: SPAIN: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 92: SPAIN: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 93: SPAIN: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 94: SPAIN: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 95: SPAIN: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 96: USAGE OF IMMUNOGLOBULINS, 2014
  • TABLE 97: ESTIMATED NO. OF HEMOPHILIA A & B PATIENTS IN THE U.K.: 2012-2014
  • TABLE 98: U.K.: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 99: U.K.: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 100: U.K.: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 101: U.K.: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 102: U.K.: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 103: TOTAL HEMOPHILIA PATIENTS IN THE ROE: 2012-2014
  • TABLE 104: ACCESS TO TREATMENTS FOR BLEEDING DISORDERS IN THE ROE
  • TABLE 105: ROE: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 106: ROE: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 107: ROE: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 108: ROE: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 109: ROE: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 110: ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 111: ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 112: ASIA-PACIFIC: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 113: ASIA-PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 114: ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 115: ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 116: CHINA: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 117: CHINA: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 118: CHINA: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2012-2021 (USD MILLION)
  • TABLE 119: CHINA: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 120: CHINA: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 121: JAPAN: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 122: JAPAN: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 123: JAPAN: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 124: JAPAN: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 125: JAPAN: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 126: NUMBER OF PATIENTS WITH BLEEDING DISORDERS: 2012-2014
  • TABLE 127: INDIA: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 128: INDIA: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 129: INDIA: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 130: INDIA: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 131: INDIA: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 132: REST OF ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 133: REST OF ASIA-PACIFIC: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 134: REST OF ASIA-PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 135: REST OF ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 136: REST OF ASIA-PACIFIC: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 137: ROW: PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 138: ROW: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 139: ROW: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 140: ROW: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 141: ROW: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 142: ROW: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 143: ESTIMATED HEMOPHILIA PATIENTS IN BRAZIL: 2012-2014
  • TABLE 144: LATIN AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 145: LATIN AMERICA: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 146: LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 147: LATIN AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 148: LATIN AMERICA: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 149: ESTIMATED HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA: 2012-2014
  • TABLE 150: PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION: 2012 & 2014
  • TABLE 151: MIDDLE EAST AND AFRICA: PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 152: MIDDLE EAST AND AFRICA: IMMUNOGLOBULIN MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 153: MIDDLE EAST AND AFRICA: COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 154: MIDDLE EAST AND AFRICA: PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 155: MIDDLE EAST AND AFRICA: PLASMA FRACTIONATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 156: GROWTH STRATEGY MATRIX, 2013-2016
  • TABLE 157: RECENT DEVELOPMENTS (2013-2016)
  • TABLE 158: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2013-2016)
  • TABLE 159: NEW PRODUCT LAUNCHES (2013-2016)
  • TABLE 160: ACQUISITIONS (2013-2016)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: IMMUNOGLOBULIN TO DOMINATE THE GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT, DURING 2016 TO 2021
  • FIGURE 7: NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 8: GLOBAL PLASMA FRACTIONATION MARKET, BY END USER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: GEOGRAPHIC SNAPSHOT: GLOBAL PLASMA FRACTIONATION MARKET IN 2015
  • FIGURE 10: GROWING USE OF IMMUNOGLOBULINS WILL DRIVE MARKET GROWTH DURING 2016-2021
  • FIGURE 11: HOSPITALS AND CLINICS ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC PLASMA FRACTIONATION MARKET, 2015
  • FIGURE 12: THE U.S. COMMANDED THE MAJOR SHARE OF THE GLOBAL PLASMA FRACTIONATION MARKET IN 2015
  • FIGURE 13: NORTH AMERICA TO DOMINATE THE PLASMA FRACTIONATION MARKET IN 2016
  • FIGURE 14: DEVELOPING MARKETS TO REGISTER HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 15: PLASMA FRACTIONATION MARKET : DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: COPD AND ASTHMA PREVALENCE, BY COUNTRY
  • FIGURE 17: GLOBAL DEATHS FROM RESPIRATORY DISEASES, 2000 VS. 2012 (THOUSAND INDIVIDUALS)
  • FIGURE 18: PLASMA COLLECTION IN EUROPE (GROSS MILLION LITERS): 2005-2013
  • FIGURE 19: SOURCE PLASMA COLLECTION IN THE U.S., 2005-2013
  • FIGURE 20: NUMBER OF HEMOPHILIA A & HEMOPHILIA B PATIENTS WORLDWIDE: 2012-2014
  • FIGURE 21: INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS
  • FIGURE 22: PLASMA FRACTIONATION MARKET IN CHINA VS. DEVELOPED COUNTRIES, 2016 VS. 2021
  • FIGURE 23: ALBUMIN MARKET SHARE IN CHINA, BY KEY PLAYER, 2015
  • FIGURE 24: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 25: PLASMA FRACTIONATION PROCESS FLOW
  • FIGURE 26: IMMUNOGLOBULIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 27: ESTIMATED LIFE-TIME RISK OF ALZHEIMER'S DISEASE, BY AGE & SEX
  • FIGURE 28: NUMBER OF PEOPLE WITH DIFFERENT BLEEDING DISORDERS, 2014
  • FIGURE 29: COAGULATION FACTOR MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 30: MEAN PER CAPITA USAGE OF FACTOR VIII (2014)
  • FIGURE 31: MEAN PER CAPITA USAGE OF FACTOR IX (2014)
  • FIGURE 32: ALBUMIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 33: NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL PLASMA FRACTIONATION MARKET FROM 2016 TO 2021
  • FIGURE 34: TREND ANALYSIS OF PRIMARY IMMODEFICIENCY PATIENTS FOLLOWED, REFERRED, IDENTIFIED, AND TREATED (2004-2013)
  • FIGURE 35: NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2014
  • FIGURE 36: GEOGRAPHIC SNAPSHOT (2016) - RAPID GROWTH MARKETS ARE EMERGING AS NEW HOTSPOTS
  • FIGURE 37: NORTH AMERICAN PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 38: NORTH AMERICA PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 39: NUMBER OF PLASMA DONATIONS IN THE U.S., 2003-2014
  • FIGURE 40: EUROPE PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 41: HEMOPHILIA A & B PATIENTS IN GERMANY, 2008 VS. 2014
  • FIGURE 42: MEAN PER CAPITA CONSUMPTION OF FACTOR VIII & FACTOR IX -2012&2014
  • FIGURE 43: APAC PLASMA FRACTIONATION MARKET SNAPSHOT
  • FIGURE 44: COMPANIES PRIMARILY ADOPTED THE STRATEGY OF EXPANSIONS FROM 2013 TO 2016
  • FIGURE 45: GLOBAL PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 46: BATTLE FOR MARKET SHARE: EXPANSIONS WAS THE KEY STRATEGY
  • FIGURE 47: GEOGRAPHIC REVENUE MIX OF THE MAJOR PLAYERS (2015)
  • FIGURE 48: COMPANY SNAPSHOT: CSL LTD.
  • FIGURE 49: COMPANY SNAPSHOT: GRIFOLS S.A.
  • FIGURE 50: COMPANY SNAPSHOT: BAXALTA INCORPORATED
  • FIGURE 51: COMPANY SNAPSHOT: OCTAPHARMA AG
  • FIGURE 52: COMPANY SNAPSHOT: KEDRION S.P.A
  • FIGURE 53: COMPANY SNAPSHOT: LFB S.A.
  • FIGURE 54: COMPANY SNAPSHOT: BIOTEST AG
  • FIGURE 55: COMPANY SNAPSHOT: SANQUIN
  • FIGURE 56: COMPANY SNAPSHOT: CHINA BIOLOGIC PRODUCTS, INC.
Back to Top